Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025

Photocure Norway

for further information on our commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com/news

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: [e-mail]

Erik Dahl
CFO
Photocure ASA
Tel: [phone]
Email: [e-mail]

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: [phone]
Email: [e-mail]

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: [phone]
Email: [e-mail]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/photocure/r/bladder-cancer--upstaging-and-risk-mitigation-with-blue-light-cystoscopy-in-nmibc-featured-at-asco-g,c4106313

The following files are available for download:

https://mb.cision.com/Main/17498/4106313/3267259.pdf

Release

 

View original content:https://www.prnewswire.co.uk/news-releases/bladder-cancer-upstaging-and-risk-mitigation-with-blue-light-cystoscopy-in-nmibc-featured-at-asco-gu-2025-302377852.html